Lung Cancer

Patients with advanced lung cancer should be tested for the 5 most common biomarkers so they may receive the best treatment options for their disease.

In the second article of this 4-part series, the authors present an overview of the current treatment landscape for NSCLC, including a description of the most often used treatments and common questions that patients can ask their providers.

LUNGevity and 4 other lung cancer organizations have provided information on the new coronavirus for people with lung cancer and other patients with cancer. This update also provides reliable sources of information for patients.

LUNGevity answers some frequently asked questions about patients with lung cancer and survivors and the coronavirus illness.

In this series of videos from LUNGevity, oncologist Zosia Piotrowska, MD, MHS, Massachusetts General Hospital, Boston, addresses many of the questions and concerns raised in regard to coronavirus COVID-19 and patients with lung cancer.

Oncologist Dr. Zosia Piotrowska addresses some specific questions about the impact of COVID-19. She discusses dealing with anxiety, symptoms, who is most at risk for the illness, how it is spread, how to avoid getting the illness, and the available treatments.

Dr. Zosia Piotrowska explains why COVID-19 is of special concern for patients with lung cancer and their caregivers. She addresses the question of treatment-related compromised immunity and the illness.

Some of the most frequently asked questions about COVID-19 include travel, social distancing, and other day-to-day matters for patients with lung cancer. Oncologist Dr. Zosia Piotrowska provides some answers.

Knowing the stage of lung cancer helps oncologists to plan the best treatment plan for each patient. This second article in the series explains how the most common type of lung cancer is staged.